Fundraising FoxRevere Pharmaceuticals
Arlington, US · Founded 2016 · Delaware corporation
Find your way into Revere Pharmaceuticals
Sign up to see every warm intro you have to Revere Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Revere Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
IR
Ian Robert SilvermanNamed on SEC filing
KP
Kollol PalNamed on SEC filing
JL
Jedd LevineNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$6.1M disclosed across 3 of 4 rounds · 2019–2023
▶$1.6MraisedJun 2023 · 22 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedJun 2023 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kollol PalDirector
- Marc LippmanDirector
- Ian Robert SilvermanExecutive Officer, Director
- Jedd LevineExecutive Officer, Director
- Offering amount
- $3.6M
- Amount sold
- $1.6M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedSep 2021 · 30 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedSep 2021 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian Robert SilvermanExecutive Officer, Director
- Marc LippmanDirector
- Kollol PalDirector
- Jedd LevineExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.1M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$3.5MraisedJan 2021 · 61 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedJan 2021 · 61 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian Robert SilvermanExecutive Officer, Director
- Kollol PalDirector
- Jedd LevineExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Revere Pharmaceuticals raised?
- Revere Pharmaceuticals has disclosed $6.1M raised across 3 of its 4 known rounds.
- Where is Revere Pharmaceuticals headquartered?
- Revere Pharmaceuticals is headquartered in Arlington, US.